NCT06772961 Effect of Percutaneous Electrical Acupoint Stimulation on the Improvement of Incidence of Adverse Respiratory Events
| NCT ID | NCT06772961 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Condition | Extubation |
| Study Type | INTERVENTIONAL |
| Enrollment | 236 participants |
| Start Date | 2025-01-25 |
| Primary Completion | 2025-11-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 236 participants in total. It began in 2025-01-25 with a primary completion date of 2025-11-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to investigate the effect of combined acupoint electrical stimulation at Taiyuan (LU9) and Hegu (LI4) on improving the incidence of respiratory adverse events after extubation in patients during the recovery period from general anesthesia. The main content of this study involves selecting patients who have undergone general anesthesia and are admitted to the Post Anesthesia Care Unit (PACU), with an expected 236 participants. The researchers will randomly assign participants to either the TEAS group or the control group using a random number table. In the TEAS group, electrodes will be applied to the upper limbs at the Taiyuan and Hegu acupoints, without intravenous infusion, and connected to a stimulation device. The stimulation will use a frequency of 2/100 Hz with sparse-dense waves, and the intensity will be adjusted to the maximum current that the patient can tolerate, starting at the time of extubation and continuing for 30 minutes. The control group will receive routine care. Throughout the process, no invasive procedures will be performed. In the PACU, the participants will: Be positioned in a 30° head-up tilt position, with continuous ECG monitoring. The SpO2 alarm on the monitor will be set to 95%. The same anesthesiologist will perform extubation according to the extubation criteria. After extubation, participants will receive routine oxygen therapy via a nasal cannula at 3L/min with a CO2 end-expiratory monitoring module attached to the other end of the cannula. Simultaneously, the TEAS group will undergo transcutaneous electrical stimulation for 30 minutes, or the control group will receive routine care. Participants will be observed in the PACU for at least 30 minutes. If no adverse events occur and the Steward score is ≥4, the patient will be deemed ready for discharge and escorted back to the ward. If there is any significant change in the patient's condition, they will be transferred to the ICU . If any respiratory-related adverse events occur, measures such as awakening the patient, supporting the jaw, increasing oxygen flow, or administering mask oxygen will be taken to ensure patient safety, and these events will be recorded in the "PACU Postoperative General Anesthesia Patient Condition Observation and Nursing Record."
Eligibility Criteria
Inclusion Criteria: * 1: Age \>18 years old. 2: ASA I-III 3: Patients undergoing elective general anesthesia surgery who are extubated upon arrival to the PACU Exclusion Criteria: * 1: Preoperative comorbidities include severe cardiovascular or respiratory diseases 2: Serious reflux aspiration during the perioperative period 3: Concurrent psychiatric disorders 4: Local skin infections or nerve damage at the upper limb Taiyuan and Hegu acupoints
Contact & Investigator
xiaoliang wang
STUDY DIRECTOR
The First Affiliated Hospital with Nanjing Medical University
Frequently Asked Questions
Who can join the NCT06772961 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Extubation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06772961 currently recruiting?
Yes, NCT06772961 is actively recruiting participants. Contact the research team at 821278639@qq.com for enrollment information.
Where is the NCT06772961 trial being conducted?
This trial is being conducted at Nanjing, China, Nanjing, China.
Who is sponsoring the NCT06772961 clinical trial?
NCT06772961 is sponsored by Nanjing First Hospital, Nanjing Medical University. The principal investigator is xiaoliang wang at The First Affiliated Hospital with Nanjing Medical University. The trial plans to enroll 236 participants.